Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Treatment of Overactive Bladder in Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Community-dwelling~* Veteran~* Self-reported urgency~* Self-reported frequent urination~* Mean of \> 8 voids per 24-hour day on bladder diary~* Able to come to clinic~Exclusion Criteria:~* Urologic surgery in the past 6 months~* Nonambulatory (unless has independent transfer skills)~* Flow rate \< 5mL at baseline and \< 10mL/sec after run-in (on simple uroflowmetry)~* Post-void residual urine volume \> 250mL at baseline and \> 150mL after run-in (on bladder ultrasound)~* Continual leakage~* Urinary tract infection (growth of \> 100,000 colonies per ml of a urinary pathogen on urine culture). May be reconsidered after treatment and negative culture.~* Fecal impaction~* Poorly controlled diabetes (glycosylated hemoglobin \>9 within last 3 months)~* Hematuria on microscopic examination in the absence of infection~* Any unstable medical condition (particularly: decompensated congestive heart failure, malignant arrhythmias, unstable angina)~  -- Impaired mental status (\< 24 on Folstein's Mini-Mental State Exam)~* Narrow angle glaucoma~* Gastric retention (by medical history)~* Hypersensitivity to tamsulosin or oxybutynin~* Current use of anticholinergic agents for detrusor instability. May be reconsidered after 2-week wash-out.~* If on diuretic, dose has not been stable for at least three months~* Sleep apnea, unless surgically corrected

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Behavioral Training (Type: EXPERIMENTAL): Behavioral training using delayed voiding, urge suppression techniques, and pelvic floor muscle training
- Drug Therapy (Type: ACTIVE_COMPARATOR): Oxybutynin chloride, extended-release, individually-titrated, 5-30 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).